BCL2 and B-cell chronic lymphocytic leukemia: These studies were largely conducted in the pre-BTK and BCL2 inhibitor era and must be interpreted cautiously due to the risk of selection bias, but they do provide some rationale to support the use of allogeneic HCT in high-risk CLL.